Breakthrough T1D (formerly JDRF) appreciates the opportunity to provide comments on the targeted evaluation by the Commission on the EU rules for medical devices and in vitro diagnostics. ABOUT BREAKTHROUGH T1D As the leading global type 1 diabetes (T1D) research and advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while driving toward cures.
BTD
Breakthrough Type 1 Diabetes
Other · United States · EU Transparency Register 623930744946-01
3
positions filed
in the 326 files tracked
3
legislative files
of 326 tracked
2
with a full position paper
attached to a submission
Counts here are a floor, never a total: they cover the 326 consultation files tracked so far (29,503 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Who they are
Among the 784 non-governmental organisations on this site, they rank #207 by legislative files engaged — a count of participation, not a measure of influence.
4
declared lobbying FTE
self-declared
—
declared costs / yr (floor)
3
EP accreditations
as declared to the register
2021
in the register since
Declares membership of
- EUDF - European Diabetes Forum
- EURADIA - Alliance for European Diabetes Research
- EU Health Policy Forum
- HTA Stakeholder Network
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026).
- Register category
- Non-governmental organisations
- Registered as
- Breakthrough T1D
- Head office
- New York, United states
- EU office
- Paris
Self-declared to the EU Transparency Register (snapshot 30 Aug 2026); cost bands are floors, not audited totals. Reused under Commission Decision 2011/833/EU.
Track Breakthrough in PolicySpeak: request access →
Work at Breakthrough Type 1 Diabetes? so we know who speaks for it.
Their record over time
Breakthrough Type 1 Diabetes filed 3 positions between 10 Jun 2025 and 19 May 2026, across 3 of the 326 legislative files tracked here, attaching a full position paper 2 times.
2025 · 2 filed2026 · 1 filed
What they argued
Breakthrough T1D (formerly JDRF) appreciates the opportunity to give comments on the Call for Evidence for an Impact Assessment on the proposed EU Biotech Act. ABOUT BREAKTHROUGH T1D As the leading global type 1 diabetes (T1D) research & advocacy organization, Breakthrough T1D helps make everyday life with type 1 diabetes better while drivingtoward cures.We do this by investing in the most promising research…
Breakthrough T1D welcomes the inclusion of diabetes in the Safe Hearts Plan and the first flagship initiative: an EU Protocol on health checks for cardiovascular diseases. However, it is essential that this and other key initiatives clearly distinguish between type 1 diabetes (T1D) and type 2 diabetes (T2D) as they differ fundamentally with respect to causes, risk-trajectory, effects, and treatments.
Looking for an argument rather than an organization? Search every submission for a phrase and see everyone who used it.
Turns up on the same files
Organizations that also filed on at least two of the same consultations. A shared interest in the same dossiers — not evidence of coordination, and we do not suggest any.
- IDEE ECONOMICHE www.idee-economiche.it · 3 files in common
- MedTech Europe · 3 files in common
- EFPIA · 3 files in common
- Deutsche Sozialversicherung Europavertretung (DSV) · 3 files in common
- European Confederation of Pharmaceutical Entrepreneurs (EUCOPE) · 3 files in common
Showing 5 of 64.
Is this your organization?
Everything on this page comes from Breakthrough Type 1 Diabetes’s own submissions to the European Commission — we have added nothing and interpreted nothing. If something is wrong or out of date, email info@policyspeak.com and we will correct it. If you are an individual named in a record, our privacy policy sets out your rights to correction, objection and removal.
Quotes are verbatim from submissions published by the European Commission, trimmed to their opening passage and never summarized by a model. Organizations only, never individuals. Reused under Commission Decision 2011/833/EU; the European Commission is not liable for this reuse.